Gene Editing Co. Nabs $100M From Private Investors
Massachusetts-based eGenesis, a life science company focused on using gene editing technology to revolutionize transplanting organs from one species to another, said Thursday that it had raised $100 million from a...To view the full article, register now.
Already a subscriber? Click here to view full article